Ranbaxy may establish production in Russia
Generic pharma company Ranbaxy (BSE: 500359), one of India’s largest drugmakers which is in the process of being acquired by Sun Pharma, is considering establishing production in Russia during the next several years, according to recent statements of Denis Manturov, Russia’s Minister of Industry and Trade.
Financial details of the project are not disclosed, however, according to some sources close to the project, the value of investments may reach $200 million.
It is planned that the plant will focus on the production of a wide range of Ranbaxy drugs, which are currently imported to Russia from abroad. Among these drugs are expected to be TSifran, Zanotsin antibiotics, as well as Ketanov and other analgesics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze